ARDELYX, INC. (ARDX)
About ARDELYX, INC.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $407.3M
- Net income
- -$61.6M
- Total assets
- $501.6M
- Market cap
- $1.4B
- Gross margin
- 90.3%
- Operating margin
- -10.1%
- Net margin
- -15.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $407.3M
- Cost of revenue
- $39.5M
- Gross profit
- $367.8M
- Operating expenses
- $408.8M
- Operating income
- -$41.0M
- Income tax
- $969.0K
- Net income
- -$61.6M
- EPS (basic)
- $-0.26
- EPS (diluted)
- $-0.26
Balance sheet
- Total assets
- $501.6M
- Current assets
- $382.3M
- Total liabilities
- $334.7M
- Current liabilities
- $88.6M
- Shareholders’ equity
- $166.9M
Cash flow
- Operating cash flow
- -$42.5M
- Investing cash flow
- -$9.0M
- Financing cash flow
- $54.5M
- Net cash flow
- $3.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.4B
- EPS (diluted)
- $-0.26
- Shares outstanding
- 273.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 19, 2014
Ardelyx, Inc. (ARDX) Stock Price
- Reported a net loss of $61.6M in FY2025.
- Revenue grew 3934% from FY2021 to FY2025.
- Gross margin of 90.3%, net margin -15.1%.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ARDELYX, INC..
Write a review
News about ARDELYX, INC.
News & sentiment via Polygon.io
Ardelyx, Inc.: frequently asked questions
Is Ardelyx, Inc. an American company?
Ardelyx, Inc. is a US-based company headquartered in Fremont, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Ardelyx, Inc. headquartered?
Ardelyx, Inc. is headquartered in Fremont, California, United States.
Is Ardelyx, Inc. publicly traded?
Yes — Ardelyx, Inc. is a publicly traded company. Its stock trades under the ticker symbol ARDX on the NASDAQ.
What does Ardelyx, Inc. do?
Ardelyx, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
